Alzheimer's Disease Neuropathology is Defined by the Accumulation of Pathological Amyloid-Beta in the Form of Senile Plaques and Dystrophic Neurites, and Phosphorylated Tau Neurofibrillary Tangles

hypothesis provisional 1,801 words

Mechanistic Model

Overview

This hypothesis establishes that Alzheimer’s disease neuropathology is defined by the accumulation of pathological amyloid-beta (Aβ) in the form of senile plaques and dystrophic neurites, and phosphorylated tau neurofibrillary tangles (NFTs) [1]. These two proteinaceous lesions form the pathological basis of the disease and drive the characteristic neurodegeneration and cognitive decline observed in Alzheimer’s Disease. [@ittner2011]

Type: Disease Model [@strooper2016]

Confidence Level: Established (Century-old consensus) [@goate1991]

Diseases Associated: Alzheimer’s Disease, Down syndrome (trisomy 21), Cerebral Amyloid Angiopathy [@strittmatter1993]

Amyloid-Beta Pathology

Production and Processing

Amyloid precursor protein (APP) undergoes proteolytic processing via two pathways: [@jonsson2012]

Non-amyloidogenic pathway: α-secretase cleavage produces sAPPα and CTFα, precluding Aβ formation
Amyloidogenic pathway: β-secretase (BACE1) and γ-secretase cleavage produces Aβ peptides [2]

The γ-secretase complex includes: [@blennow2018]

Presenilin 1 (PSEN1) — catalytic subunit
Presenilin 2 (PSEN2) — alternate catalytic subunit
Aph-1, Pen-2, Nicastrin — accessory subunits

Aβ Peptide Species

| Species | Length | Aggregation | Toxicity | [@jack2018] |---------|--------|-------------|----------| [@palmqvist2024] | Aβ1-38 | 38 aa | Low | Minimal | [@jankord2024] | Aβ1-40 | 40 aa | Moderate | Moderate | [@oddo2003] | Aβ1-42 | 42 aa | High | High | [@van2023] | Aβ1-43 | 43 aa | Very high | Very high | [@sims2023]

Aβ42 and Aβ43 are more aggregation-prone and form the core of senile plaques [3].

Plaque Types

Diffuse plaques: Non-fibrillar Aβ deposits, often in pre-clinical stages
Core plaques: Dense-core Aβ with neuritic components
Plaques with dystrophic neurites: Neuronal processes surrounding plaques
Cerebral amyloid angiopathy (CAA): Aβ deposition in blood vessel walls [4]

Dystrophic Neurites

Dystrophic neurites are swollen, tortuous neuronal processes surrounding amyloid plaques:

Accumulate in response to local Aβ toxicity
Contain phosphorylated tau, ubiquitin, and other proteins
Represent early sign of neuronal injury
Correlate with local synaptic loss [5]

Tau Pathology

Tau Biology

Tau is a microtubule-associated protein encoded by the MAPT gene:

Six isoforms (0N3R to 4N4R) via alternative splicing
Binds to and stabilizes microtubules
Primarily expressed in neurons
Regulates axonal transport and synaptic function [6]

Hyperphosphorylation

In AD, tau becomes abnormally phosphorylated at >45 sites:

Key phosphorylation sites:

Ser202/Thr205 (AT8 epitope)
Thr212/Ser214 (AT100 epitope)
Ser396/Ser404 (PHF-1 epitope)
Thr181 (CSF biomarker)

Kinases involved:

GSK-3β — primary tau kinase
CDK5 — neuronal tau kinase
MAPK family members [7]

Neurofibrillary Tangles

NFTs consist of paired helical filaments (PHFs) and straight filaments:

Pretangles: Soluble hyperphosphorylated tau in cytoplasm
Intracellular NFTs: Fibrillar tau in neuronal soma
Extracellular NFTs: “Ghost tangles” after neuron death

NFTs follow a predictable anatomical progression (Braak staging) [8]:

Stage	Regions Affected	Clinical Correlation
I-II	Transentorhinal	Preclinical
III-IV	Limbic (hippocampus, amygdala)	MCI
V-VI	Isocortical	Dementia

Relationship Between Aβ and Tau

The Amyloid Cascade Hypothesis

The amyloid cascade hypothesis posits that Aβ accumulation is the primary trigger:

Aβ accumulation → synaptic dysfunction
Synaptic loss → tau hyperphosphorylation
NFT formation → neuronal death
Neurodegeneration → cognitive decline [9]

Evidence for Aβ-Tau Interaction

Supporting evidence:

Aβ promotes tau pathology in animal models [10]
Tau facilitates Aβ toxicity [11]
Spatial correlation between plaques and NFTs
Genetic evidence (APP, PSEN1, PSEN2, APOE)

Challenging evidence:

Plaque burden doesn’t correlate with cognitive decline
NFT burden strongly correlates with cognitive status
Aβ-independent tauopathies exist
Many elderly have plaques without dementia

Updated Model: Multi-hit Hypothesis

Current models suggest Aβ initiates a cascade, but multiple factors determine progression:

Aβ as an “amplifier” rather than sole cause
Tau spread via trans-synaptic mechanisms
Role of neuroinflammation, glial activation
Genetic modifiers (APOE, TREM2) [12]

Evidence Assessment

Confidence Level: Established

Evidence Type	Strength	Key Studies
Histopathology	Strong	[1, 4, 8]
Genetic Studies	Strong	[13, 14, 15]
Biomarker Studies	Strong	[16, 17, 18]
Animal Models	Strong	[19, 20]
Clinical Trials	Moderate	[21, 22]

Key Supporting Studies

Katzman (1988) — Established Aβ plaques and NFTs as the defining lesions of AD [1]
Goate et al. (1991) — First PSEN1 mutation linked to familial AD [13]
Strittmatter et al. (1993) — APOE ε4 as major genetic risk factor [14]
Braak & Braak (1991) — Systematic staging of NFT pathology [8]
Jack et al. (2018) — AT(N) biomarker classification framework [17]

Testability Score: 10/10

Post-mortem histopathology definitively identifies both lesions
PET ligands detect plaques (Flutemetamol, Florbetapir) and tau (Flortaucipir) in vivo
CSF biomarkers measure Aβ42, total tau, and phosphorylated tau
Multiple therapeutic trials target Aβ and tau

Therapeutic Potential Score: 8/10

Three anti-Aβ antibodies now FDA-approved (Lecanemab, Donanemab, Aduhelm)
Active tau immunotherapy trials in progress
Earlier intervention correlates with better outcomes

Key Proteins and Genes

Protein/Gene	Role	Relevance
APP	Aβ precursor	Genetic cause of familial AD
PSEN1	γ-secretase	Most common familial AD gene
PSEN2	γ-secretase	Less common familial AD
APOE	Lipid transport	Major genetic risk factor
TREM2	Microglial receptor	Genetic risk factor (late onset)
MAPT	Tau protein	Tau gene, risk for tauopathies
BIN1	Bridging integrator	GWAS hit for sporadic AD

Clinical Implications

Diagnostic Criteria

The NIA-AA research framework uses biomarker evidence:

A+ (Amyloid positive): PET or CSF evidence
T+ (Tau positive): PET or CSF evidence
N+ (Neurodegeneration): Atrophy, hypometabolism, or elevated t-tau

“AD” is now defined by A+T+ status, regardless of clinical symptoms [17].

Biomarker Staging

Stage	Biomarkers	Clinical
Preclinical	A+ T- N-	Normal cognition
MCI due to AD	A+ T+ N-	Mild impairment
Dementia due to AD	A+ T+ N+	Dementia

Therapeutic Implications

Approved anti-amyloid therapies:

Lecanemab (Leqembi): Aβ protofibril antibody, 27% slowing of decline [21]
Donanemab (Kisunla): N-terminal Aβ antibody, 35% slowing of decline [22]

In development:

Tau immunotherapies (Semorinemab, Tilavonemab)
BACE inhibitors (stopped due to side effects)
Aggregation inhibitors

Related Hypotheses

In Alzheimer’s disease, biomarker events occur in a specific temporal sequence — Aβ first, then tau, then neurodegeneration
Amyloid plaque and neurofibrillary tangle deposition relationship — mechanistic interaction
Alterations in intra-regional functional connectivity — Aβ and tau drive connectivity changes